Skip to main navigation Skip to search Skip to main content

Dexamethasone-suppressed corticotropin-releasing hormone stimulation test in morbid obese adults

  • Leonard Saiegh
  • , Dean Keren
  • , Tova Rainis
  • , Mohammad Sheikh-Ahmad
  • , Maria Reut
  • , Afif Nakhleh
  • , Irit Wirsansky
  • , Limor Chen-Konak
  • , Elad Schiff
  • , Carmela Shechner
  • Bnai-Zion Medical Center

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Purpose In order to differentiate between Cushing's syndrome (CS) and Pseudo-Cushing's syndrome, it is customary to use a test that is conducted by cortisol suppression with low-dose dexamethasone, followed by the administration of corticotropin releasing hormone (Dex-CRH test). In children with severe obesity, Dex-CRH test has shown a specificity of 55%. The aim of current study was to evaluate the specificity of Dex-CRH test in morbid obese adults. Methods The study included a total of 19 subjects with a body mass index (BMI) equal or higher than 40 kg/m2. In all subjects Dex-CRH test was performed, and 24 h urinary free cortisol was collected prior the test and during the second day of dexamethasone administration (2nd-day-UFC). Results BMI was 45.1 ± 4.6 kg/m2 and 45.7 ± 3.3 kg/m2 in women and men, respectively. 14 subjects underwent bariatric surgery. No subject had surgical or perioperative complications and surgically treated subjects had mean body weight loss of 46.5 ± 16.6 kg. All except for 2 subjects had normal Dex-CRH test, as 15-min cortisol falling below 1.4 μg/dl. During follow-up, no subject gained additional weight, neither developed signs of CS. 15-min-cortisol concentration of 1.4 μg/dl revealed a specificity of 89% and 2nd-day-UFC of 16 μg/24 h showed a specificity of 100%. Conclusions Morbid obesity in adults seems not to comprise a significant confounder in Dex-CRH test, and 15-min-cortisol concentration of 1.4 μg/dl had a higher specificity than previously reported in obese children.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalObesity Research and Clinical Practice
Volume10
Issue number3
DOIs
StatePublished - 1 May 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Asia Oceania Association for the Study of Obesity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Corticotropin-releasing hormone
  • Cushing's syndrome
  • Dexamethasone
  • Obesity

Fingerprint

Dive into the research topics of 'Dexamethasone-suppressed corticotropin-releasing hormone stimulation test in morbid obese adults'. Together they form a unique fingerprint.

Cite this